Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2020

View Archived Issues

CAR-T therapy as powerful salvage approach in patients with R/R AL with TP53 alterations

PPARgamma controls antifibrotic network

Viral infection may be second hit for familial ALS

ZBP1 as a new therapeutic target in multiple myeloma

JNJ-7706621 reverses resistance to CD37-targeted radioimmunotherapy in DLBCL

Celgene presents first-in-human data for CC-90009

Cadila Healthcare divulges new antimycobacterial compounds

Chiesi Farmaceutici identifies ROCK1 and ROCK2 inhibitors

BioTheryX presents new compounds for cancer

Chemrar Research & Development Institute discloses dopamine D2 and D3 receptor agonists

New muscarinic M1 receptor antagonists presented by Pipeline Therapeutics

Durect discontinues development of DUR-928 for psoriasis

Opiant signs letter of intent with NCATS to collaborate on OPNT-004 development

Novel copy number genetic variants identified in Diamond Blackfan anemia

Orphazyme reports new data and analysis supporting arimoclomol in NPC

Phase III GRAVITAS-301 study of itacitinib in treatment-naive GvHD misses primary endpoint

Civi Biopharma studies PCSK9 inhibitor CIVI-007 in phase IIa study

Novan reports topline efficacy data from phase III B-SIMPLE program of SB-206 for molluscum

Glutamine transporter variant identified as new cancer target

Taiwan FDA approves Lumosa's IND for LT-5001 for uremic pruritus

Sol-Gel initiates phase I study of SGT-210 in punctate palmoplantar keratoderma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...